Clinical Trials Logo

Clinical Trial Summary

Background: Metabolism refers to the many chemical pathways by which various compounds, including food, are processed and used in the body. People with non-alcoholic fatty liver disease (NAFLD) have too much fat in their liver cells, but what causes it is unclear. One explanation is that people with NAFLD process food and metabolize it differently than people without NAFLD. Researchers want to compare how food is metabolized in people with and without NAFLD. Objective: To better understand how food intake influences the development and progression of NAFLD. Eligibility: People ages 18 and older with NAFLD or with a non-NAFLD metabolic syndrome Healthy volunteers ages 18 and older Design: Participants will be screened with medical history, surveys, physical exam, and blood tests. This will have ultrasound of the abdomen. This uses sound waves to image internal organs. Participants will stay at the Clinical Center for 2 nights. They will fast he first night. On the second day they will: Have their metabolism monitored in a metabolism research room for 24 hours Have a catheter inserted into an arm vein for several blood tests Drink an Ensure Plus for breakfast Have solid meals for lunch and dinner Have several urine tests. The final morning, they will: Have more blood tests. Have a DXA test to measure the fat in the body. They will lie on their backs for 15-25 minutes while an x-ray machine is positioned over areas of the body.


Clinical Trial Description

Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder in the Western world and is a leading cause of liver-related morbidity and mortality. Excessive caloric intake and specific nutritional components have been implicated in its pathogenesis, but the complex metabolic pathways linking nutrient consumption with hepatic fat accumulation have not yet been fully elucidated. Analysis of pathophysiology and the search for biomarkers in NAFLD has largely focused on fasting samples; the dynamic response to a caloric load has not been interrogated, beyond glucose tolerance testing. Metabolomics is a novel high-throughput technique, allowing for simultaneous detection of hundreds to thousands of metabolites, and the evaluation of their interconnectivity and causal relationships. We propose a pilot study to investigate the metabolic response of patients with NAFLD to a standardized food challenge, by applying a metabolomics-based dynamic approach. In this study we will recruit up to 50 patients with NAFLD and compare them to 12 controls with metabolic syndrome without NAFLD, and 12 healthy controls. Following an overnight fast, subjects will be situated in a metabolic chamber for continuous measurement of metabolic rates and will be given a liquid mixed meal containing approximately 30% of daily caloric requirement over a period of 15 minutes. The energy expenditure (EE) and respiratory quotient (RQ), reflecting preference for carbohydrate or fat oxidation, will be measured at 1-minute resolution. Blood will be drawn at baseline, and at 30 min, 1, 2, 4 and 24 hours after ingestion. Plasma will be separated and stored in -80 (Infinite)C. Following completion of recruitment, stored samples will be analyzed at the NCI Laboratory of Metabolism by LC/MS and GC/MS, metabolites of interest identified, and individual metabolites quantitated and normalized to their pre-prandial level. Study results will hopefully identify novel metabolic markers of disease, and uncover altered signaling pathways unique to NAFLD that are activated primarily under fed state conditions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02520609
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase
Start date October 28, 2015
Completion date May 14, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT06051669 - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Not yet recruiting NCT05984745 - Effect of CoQ10 on the Outcome of MAFLD Patients Phase 2
Completed NCT02565446 - Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram N/A
Not yet recruiting NCT01694342 - Telomere Parameters in Patients With Nonalcoholic Fatty Liver N/A
Completed NCT01464801 - Resveratrol in Patients With Non-alcoholic Fatty Liver Disease N/A
Completed NCT01992809 - Omega 3 Supplementation in Fatty Liver Phase 3
Completed NCT00244569 - Development of a Breath Test for Monitoring Patients With Liver Disease Phase 3
Completed NCT00063635 - Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Phase 3
Recruiting NCT03972319 - Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study Early Phase 1
Completed NCT03141008 - Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
Completed NCT03614039 - Effect of Probiotic and Smectite Gel on NAFLD N/A
Recruiting NCT05125757 - Lifestyle Modification in Psoriatic Patients With Fatty Liver N/A
Recruiting NCT05370053 - The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology N/A
Recruiting NCT04371042 - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Completed NCT04004273 - Diabetes, Exercise and Liver Fat (DELIVER) N/A
Recruiting NCT02265276 - A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease Phase 3
Completed NCT02347007 - Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults N/A
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3
Completed NCT01234714 - Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications N/A